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Abstract
Background: Multiple studies regarding the use of Resuscitative Endovascular Balloon Occlusion of the
Aorta (REBOA) in patients with non-compressible torso injuries and uncontrolled haemorrhagic shock were recently
published. To date, the clinical evidence of the efficacy of REBOA is still debated. We aimed to conduct a systematic
review assessing the clinical efficacy and safety of REBOA in patients with major trauma and uncontrolled
haemorrhagic shock.
Methods: We systematically searched MEDLINE (PubMed), EMBASE and CENTRAL up to June 2020. All randomized
controlled trials and observational studies that investigated the use of REBOA compared to resuscitative
thoracotomy (RT) with/without REBOA or no-REBOA were eligible.
We followed the PRISMA and MOOSE guidelines. Two authors independently extracted data and appraised the risk
of bias of included studies. Effect sizes were pooled in a meta-analysis using random-effects models. The quality of
evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation
methodology. Primary outcomes were mortality, volume of infused blood components, health-related quality of life,
time to haemorrhage control and any adverse effects. Secondary outcomes were improvement in haemodynamic
status and failure/success of REBOA technique.
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: silvia.gianola@grupposandonato.it
†Greta Castellini and Silvia Gianola are co-first authors.
†Primiano Iannone and Osvaldo Chiara are co-last authors.
1IRCCS Istituto Ortopedico Galeazzi, Unit of Clinical Epidemiology, Milan, Italy
Full list of author information is available at the end of the article
Castellini et al. World Journal of Emergency Surgery           (2021) 16:41 
https://doi.org/10.1186/s13017-021-00386-9
Results: We included 11 studies (5866 participants) ranging from fair to good quality. REBOA was associated with
lower mortality when compared to RT (aOR 0.38; 95% CI 0.20–0.74), whereas no difference was observed when REBOA
was compared to no-REBOA (aOR 1.40; 95% CI 0.79–2.46). No significant difference in health-related quality of life
between REBOA and RT (p = 0.766). The most commonly reported complications were amputation, haematoma and
pseudoaneurysm. Sparse data and heterogeneity of reporting for all other outcomes prevented any estimate.
Conclusions: Our findings on overall mortality suggest a positive effect of REBOA among non-compressible torso
injuries when compared to RT but no differences compared to no-REBOA. Variability in indications and patient
characteristics prevents any conclusion deserving further investigation. REBOA should be promoted in specific training
programs in an experimental setting in order to test its effectiveness and a randomized trial should be planned.
Keywords: Systematic review, Resuscitative Endovascular Balloon Occlusion of the Aorta, Major trauma haemorrhage,
Resuscitative thoracotomy
Background
Haemorrhage from non-compressible torso injuries is a
leading cause of death in military and civilian trauma
[1]. To control exsanguinating bleeding from non-
compressible torso injuries, a damage control approach
should be used. A variety of damage control surgery
techniques have been developed to limit blood loss, con-
trol contamination and preserve one’s physiology such
as abdominal packing, non-essential organ removal,
extra-peritoneal packing, stapler resection of the bowel,
vascular shunts and interventional radiology with
embolization procedures.
Resuscitative thoracotomy is commonly used in patients
in extremis or cardiac arrest for open cardiac massage and
aortic cross-clamping [2, 3]. Resuscitative Endovascular
Balloon Occlusion of the Aorta (REBOA) is a technique
for temporary cessation or limitation of blood flow
through the aorta, which may be used as a bridge until de-
finitive control of the bleeding by endovascular procedures
or surgery is performed [4]. After emergency room
extended focused assessment sonography for trauma (E-
FAST) and chest and pelvis x-ray, the balloon can be in-
flated in the descending thoracic aorta (zone 1) to reduce
blood flow below the diaphragm or in the abdominal aorta
below the renal arteries (zone 3) to stop bleeding from the
pelvis and lower extremities.
The application of a REBOA has been suggested in the
following cases: (i) in zone 1 for imminent traumatic
cardiac arrest for probable haemorrhagic cause [5]; (ii)
in zone 1 for severe haemorrhagic shock due to abdom-
inal and/or pelvic injuries [6, 7]; (iii) in zone 3 for severe
pelvic fracture [7, 8] or to control junctional bleeding
from the groin end lower extremities; (iv) in zone 1 for
penetrating thoracic trauma, according to an algorithm
proposed in 2020 [9].
In recent years, REBOA has received a lot of attention
for its applicability and promise in adult major trauma
settings. It is a less invasive method of haemodynamic
control in severe haemorrhagic settings relative to other
damage control techniques. Survival benefits between
REBOA and non-REBOA in severe abdominal-pelvic
haemorrhage and between REBOA and resuscitative
thoracotomy (RT) in imminent cardiac arrest for haem-
orrhage are controversial. All procedures may lead to
unintended adverse effects [10] and this underlines the
need for shared indications for the use.
The aim of this systematic review was to explore to
the best of current knowledge if REBOA is clinically safe
and effective in the management of major exsanguin-
ation from torso injuries due to trauma.
Methods
We conducted a systematic review to support the major
trauma integrated management guideline panel of the
Italian National Institute of Health (Istituto Superiore di
Sanità) in formulating recommendations [11]. Following
the GRADE-ADOPOLMENT methodology [12] and in
accordance with the standards defined by the Sistema
Nazionale Linee Guida (SNLG) [13], the multidisciplinary
panel decided to develop a “de novo” question addressing
the efficacy of Resuscitative Endovascular Balloon Occlu-
sion of the Aorta (REBOA) on patients with major trauma.
The clinical question addressed in this systematic review
was: Is Resuscitative Endovascular Balloon Occlusion of
the Aorta (REBOA) clinically effective in the Management
of major exsanguination in trauma?
Registered protocol
The protocol of the present systematic review is stored
at the following link: https://osf.io/ntxvj/. We conducted
the systematic review following the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)
statement and the Meta-Analysis of Observational Studies
in Epidemiology (MOOSE) guideline [14, 15].
Inclusion criteria
Randomized controlled trials (RCT) and/or observa-
tional studies were included if they met the following
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criteria: (1) population: children, young people and
adults experiencing major trauma, blunt or penetrating;
(2) intervention: REBOA; (3) comparison: RT (with/with-
out REBOA) or no REBOA intervention; (4) setting: pre-
hospital, emergency department and operating room
resuscitation phase. Studies including patients with
trauma resulting from burns were excluded.
Outcome measures and follow-up assessment
Primary outcome measures selected for the analyses
were as follows: (i) 24-h mortality, 30 days to 12 months
mortality; (ii) volume of infused blood components; (iii)
health-related quality of life (e.g. Discharge Glasgow
Coma Scale); (iv) adverse effects (e.g. amputation); (v)
time to haemorrhage control. Secondary outcomes were
as follows: (vi) improvement in haemodynamic status
and (vii) failure/Success of REBOA technique.
Search strategy
Two professional librarians interviewed the following
electronic databases: MEDLINE (PubMed), EMBASE
(Elsevier, EMBASE.com) and CENTRAL up to June 9,
2020, with language restricted to English, Italian,
Spanish, French, German using the search strategy out-
lined in Supplement A. We checked the reference lists
of all studies included and of any systematic reviews we
identified during the search process (including grey lit-
erature and conference proceedings). We also searched
for ongoing trials (i.e. clinical trials.gov).
Study selection and data extraction
Two independent authors (SG, GC) screened titles and
abstracts by the search strategy. Following the first
phase, they independently assessed the full text of poten-
tially relevant studies for inclusion. Any disagreement
was solved by a discussion with one of the authors (OC).
A standardized data collection form was used to extract
the following information: (i) study characteristics: study
design, setting, countries and settings, funding; (ii) par-
ticipant’s characteristics, sample size and type of trauma;
(iii) intervention type and outcomes. The authors of the
selected studies were contacted if the reported data were
not reported in detail or were incomplete. We hand
searched potential references from lists of included
studies.
Internal validity
The internal validity of the included studies was assessed
using the Cochrane Risk of Bias (RoB) tool for RCTs
[16] and the Newcastle-Ottawa scales [17] for observa-
tional studies. The following domains of the Cochrane
RoB tool were appraised: selection bias (random
sequence generation and allocation concealment), per-
formance bias (blinding of participants and personnel),
detection bias (blinding of outcome assessment), attri-
tion bias (incomplete outcome data) and reporting bias
(selective reporting) (58). Each domain was classified as
“high”, “low” or “unclear” RoB if the study did not pro-
vide sufficient information to be classified.
In the Newcastle-Ottawa scales, the following domains
were appraised: selection, comparability, outcome.
Thresholds for converting the Newcastle-Ottawa scales
to Agency for Healthcare Research and Quality stan-
dards (good, fair and poor) were adapted. Two reviewers
(SG, GC) independently evaluated the methodological
quality of the included studies; any disagreement was re-
solved by a consensus between reviewers.
Data synthesis
The treatment effects for dichotomized outcomes were
evaluated using the odds ratio (OR), and when studies
adopted strategies to minimize confounding factors (e.g.
adjustment propensity score/multivariable analyses), the
adjusted odds ratio (aOR) was adopted; for continuous
outcomes, the pooled mean difference (MD), or stan-
dardized mean difference (SMD) for different outcome
measurements, was used. The variance was expressed
with 95% confidence intervals (95% CI). When applic-
able, the outcome measures from the individual trials
were combined through meta-analysis using random-
effects models described by DerSimonian and Laird [18]
because a certain degree of heterogeneity of population
and treatments would be expected among interventions.
Both crude and adjusted pooled treatment effects were
reported in tables as well as in forest plots. A subgroup
analysis for every included comparison was finally
planned in order to better answer different questions (vs
RT, v. RT + REBOA, vs no-REBOA). All tests were con-
sidered statistically significant, for p values less than
0.05. The analyses were performed by using RevMan
Version 5.4 (Nordic Cochrane Center) [19].
Quality of evidence
The quality of evidence of each outcome was judged
through five dimensions (risk of bias, consistency of
effect, imprecision, indirectness and publication bias) by
the GRADE approach [20]. The evidence was down-
graded from “high quality” by one level if serious, or by
two levels if very serious limitations were found for each
of the 5 dimensions. We presented a summary of
findings describing the treatment effects, the quality of
evidence and the reasons for limitations.
Results
Study selection
A total of 324 publications were selected for the analysis.
No randomized controlled trials were found, one regis-
tered trial protocol not completed, five systematic reviews
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of observational studies and 10 observational studies met
the eligibility criteria. A comparative evaluation between
studies included in the systematic reviews and the primary
studies resulting from the search strategy was performed:
at the end of the search, 11 primary observational studies
were included [21–31]. The flow diagram is reported in
Supplement B.
General characteristics
Overall, five studies assessed the comparison REBOA vs
RT [21–24, 29], one study reported the comparison
REBOA vs RT + REBOA [28] and five studies investi-
gated the comparison REBOA vs no-REBOA [25–27, 30,
31]. Two of the selected studies were prospective [23,
24] and nine were retrospective [21, 22, 25–31]. The me-
dian injury severity score (ISS) across studies ranged
from a minimum of 25 (IQR: 16–25) [25] and a max-
imum of 44 (IQR: 38–59) [28]. Blunt trauma was the
most representative feature of patients across studies,
except for one study that included only patients with
penetrating trauma [25]. General characteristics are re-
ported in Table 1.
Overall mortality
All studies (n = 11) reported overall mortality data
(Table 2). Most of these (n = 9) did not report the time
from injury to death, similarly for the outcome at dis-
charge without a specific time frame. In addition, five
studies evaluated overall mortality in the emergency
department, while four studies assessed the mortality
at 24 h and three studies reported data at 1 month
(Supplement C).
Crude summary estimates found statistically signifi-
cant differences in favour of REBOA when compared to
RT (OR 0.42; 95% CI 0.32–0.54, I2 = 0) or RT with
REBOA (OR 0.13; 95% CI 0.04–0.47) and against
REBOA when compared to no-REBOA (OR 0.68; 95%
CI 1.03–2.72, I2 = 87). Adjusted summary estimates con-
firmed a statistically significant difference favouring
REBOA vs. RT (aOR 0.38; 95% CI 0.20–0.74, I2 = 37),
whereas no significant difference was present when
REBOA was compared to no-REBOA (aOR 1.40; 95% CI
0.79–2.46, I2 = 90). Figure 1 a shows the crude pooled
treatment effects, whereas Fig. 1 b shows the adjusted
pooled treatment effects of overall mortality of the stud-
ies that provided data at discharge or at the last available
follow-up adjusted by matching with the propensity
score or by regression. Figure 2 shows mortality in
the emergency department, while Fig. 3 presents 24-h
mortality. Individual studies investigated mortality at
1 month for RT vs REBOA [28] (aOR not estimable)
and REBOA vs. no-REBOA (aOR 0.77, 95% CI 0.36–
1.61) [27, 30], without evidence of significant effects
(Supplement C).
Volume of infused blood components
Six studies investigated the volume of blood compo-
nents. Some studies demonstrated a statistically signifi-
cant decrease in the number of plasma [24, 25] and
platelets [27] infused to the patients and in the number
of patients who needed transfusion [30]. However, het-
erogeneity in the reporting of outcome measurements
prevents a quantitative analysis and data are reported in
Table 3.
Health-related quality of life
The Discharge Glasgow Coma Scale (Discharge GCS)
among survivors, as a proxy of health-related quality of life
outcome, was reported in four studies [23, 24, 27, 31].
A study [24] found no significant differences between
the 2 groups (median REBOA group, 15 points; median
RT group, 15 points, p = 0.766) reported, and in another
study [23], the Discharge GCS was in favour of the
REBOA group, but only in the pre-hospital cohort
(median REBOA group, 9 points; median RT group, 3
points, p = 0.026).
In the last two studies [27, 31] only a subgroup ana-
lysis in patients who received REBOA was performed.
Surviving patients had higher Glasgow Coma Scale
(GCS) than non-survivors in both Norii et al., 2015
(mean GCS, 11.6 survivors vs. 7.2 non-survivors, p =
0.0001) and Joseph et al. 2019 studies (median (IQR) GCS,
15 (13-15) survivors vs 3 (3-13) non-survivors, p = 0.04).
Adverse effects
Adverse events for both groups of treatment (REBOA
vs. RT) were reported in three studies [23, 24, 27],
whereas one study [25] reported adverse events only for
the REBOA group. Overall, the most frequently reported
complications from the studies were amputation, haema-
toma and pseudo-aneurysm, shown in Supplement C.
Other outcomes
Two studies reported the number of subjects in which
the technique was successfully performed (> 91%) [23,
24]. Two studies reported the temporary time to control
haemorrhage [27, 28]. One study [28], investigating
REBOA vs REBOA +RT, reported the control time for
bleeding from arrival at the scene. Patients with arterial
access achieved within 21.5 min of arrival demonstrated
immediate subsequent haemostasis. Heterogeneous mea-
surements for the improvement in haemodynamics
(blood pressure and heart rate) are reported in two stud-
ies [23, 24]. Supplement C descriptively reported data.
Internal validity and quality of evidence
Seven studies were judged to be of good quality and four
of fair quality (Supplement D). Certainty of evidence
ranged from very low to low with no serious risk of bias.
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Table 1 General characteristics
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We downgraded the evidence for serious indirectness
and imprecision of the estimates (Supplement E).
Algorithm for decision-making
REBOA might be considered in haemodynamically un-
stable patients, unresponsive to initial resuscitation for a
suspected torso haemorrhage, as indicated by E-FAST
positive for free peritoneal fluid and/or pelvis x-ray indi-
cating fracture of the ring. REBOA is inflated in zone 1
if positive E-FAST or impending cardiac arrest and zone
3 if pelvic fracture. REBOA is progressively deflated as
soon as the bleeding site is controlled with temporary or
definitive surgical techniques, while continuing volume
replacement. REBOA is not indicated in the suspicion of
injury of the thoracic aorta and if emergency room diag-
nostic tools fail to demonstrate a torso haemorrhage.
Figure 4 describes an algorithm for REBOA indications.
Discussion
To our knowledge, this is the first comprehensive
systematic review and meta-analysis assessing all com-
parisons between REBOA and RT and REBOA versus
no-REBOA, considering many critical and important
outcomes. With low quality of evidence, adjusted overall
estimates found a difference in favour of REBOA when
compared to RT (aOR 0.38; 95% CI 0.20–0.74). With
Table 1 General characteristics (Continued)





Japan Trauma Data Bank Severely injured patients
Blunt trauma (96% REBOA; 94%
controls)






Survival at 28 days, a composite of in-
hospital death, transfusion in number of
patients
Legend: AO open aortic occlusion, ACC resuscitative open aortic cross-clamping, BMI body mass index, JCS Japan Coma Scale, ED emergency
department, NCTH non-compressible torso haemorrhage, RTS revised trauma score, RT resuscitative thoracotomy with aortic cross-clamping, TMPM-ICD9
the Trauma Mortality Prediction Model based on the ICD 9th Revision, TRISS Trauma and Injury Severity Score
Table 2 Overall in-hospital mortality. Data are collected for the last available observation when time of follow up is specified
Overall mortality REBOA Control Time/setting OR adjusted/matched Description of
adjustmentN Tot % n Tot %
Aso 2017 [22] (REBOA vs RT) 90 191 47 48 68 70.6 Time frame not
reported
Hazard ratio = 0.94; 95%CI =
0.60–1.48§
OR 0.821; 95% CI 0.306–1.234
Adjusted propensity
score
Brenner 2018 [23] (REBOA vs RT) 75 83 90.3 197 202 97.5 24 h OR = 0.24; 95% CI 0.08–0.75 None
Abe 2016 [21] (REBOA vs RT) 405 636 63.7 210 267 78.7 Time frame not
reported
ED
OR 0.261 95%CI 0.130–0.523
Pair-matched n = 304
Adjusted propensity
score
DuBose 2016 [24] (REBOA vs RT) 33 46 71.7 57 68 83.8 ED
24 h
OR = 0.263; 95% CI = 0.043–1.609 not reported
(regression)




Matsumara 2017 (REBOA vs
REBOA+RT)




Nori 2015* [31] (REBOA vs no-REBOA) 259 351 73.8 709 1456 48.7 Time frame not
reported




García 2020 [25] (REBOA vs no-REBOA) 5 28 17.8 48 317 15.1 Time frame not
reported
OR = 0.20; 95%CI 0.05–0.77 Adjusted propensity
score
Inoue 2016* [26] (REBOA vs no-
REBOA)
386 625 61.7 283 625 45.3 Time frame not
reported
ED
OR = 1.95, 95% CI 1.56–2.45 Adjusted propensity
score °
Joseph 2019* [27] (REBOA vs no-
REBOA)
50 140 35.7 53 280 18.9 ED
overall
OR= 2.38; 95% CI= 1.51–3.76 Adjusted propensity
score
Yamamoto 2019* [30] (REBOA vs no-
REBOA)
64 117 54.7 79 117 67.5 Time frame not
reported
OR = 0.58; 95% CI = 0.34–0.99 Adjusted propensity
score
§To be able to pool the adjusted odds ratios in a meta-analysis, the hazard ratio reported in the study by Aso et al. 2017 [22] was converted to an odds
ratio. For the procedure, we assumed that the hazard ratio is a type of relative risk and, thus, is asymptotically similar to a relative risk. Then, using the
inverse probability weighted binomial model we transformed the adjusted hazard ratio of mortality reported in the study by Aso to an odd ratio.
Following this approach, we obtained an adjusted odds ratio of mortality (Aso: OR 0.821; 95% CI 0.306–1.234)
*Data were reported only for pairs
°Mortality was estimated via linear regression analysis, and time variables were estimated via bootstrapping
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very low quality of evidence, REBOA when compared to
no-REBOA (aOR 1.40; 95% CI 0.79–2.46) did not show
a significant difference in outcomes. Adverse events were
poorly reported across studies: only four studies re-
ported complications such as amputation, haematoma
and pseudoaneurysm.
Our literature search found five systematic reviews
about the use of REBOA. However, two investigated the
REBOA in a variety of clinical settings [10, 32], and one
focussed only on adverse events revising case series
studies [33]. Our results are consistent with other two
systematic reviews [34, 35] where the comparison of
REBOA versus RT found similar quantitative findings
(aOR 0.42; 95%CI 0.17–1.03; OR 0.25; 95%CI 0.11–0.56,
respectively). Nevertheless, our review updated the evi-
dence including the last three years of publication.
All the studies where REBOA was compared to RT
[21–24, 29] demonstrated a clear survival benefit in very
sick patients. This statistical significance can be biased
since the most serious patients in cardiac arrest or
imminent cardiac arrest undergo a RT, while more
stable patients might be considered for REBOA. In very
sick patients with very low critical tissue and organ per-
fusion or impending cardiac arrest, extreme resuscitative
manoeuvres are required as a bridge to save time to de-
finitive bleeding control or other potential reversible in-
jury management. RT is a maximally invasive procedure
in the trauma setting with a survival of less than 10%
a b
Fig. 1 a Overall crude odds ratios for in-hospital mortality (REBOA vs control – subgroups: vs RT; vs RT with REBOA; vs no-REBOA). b Overall
adjusted odds ratios for in-hospital mortality (REBOA vs control — subgroups: vs RT; vs RT with REBOA; vs no-REBOA)
Fig. 2 Adjusted odds ratios for mortality in ED (REBOA vs control — subgroups: vs RT; vs no-REBOA)
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but associated with a negative perception because often
used as the last resort in patients beyond saving [36, 37].
In this comparison, patient selection separates patients
into the dead-or-nearly-dead (RT) and the alive-but-
severe-shock (REBOA) with no valid conclusions regard-
ing the superiority or preference of REBOA over RT.
Therefore, in the absence of randomized trials, REBOA
can only be considered an option for the clinician in
very sick haemorrhagic patients following trauma. The
more valuable contribution to the literature should come
from the comparison of REBOA and no-REBOA. How-
ever, when REBOA has been compared with no-REBOA
in our analyses [25–27, 30] a clinical benefit was not ob-
served. The available published studies range from very
low and low certainty of evidence, including patients
with brain injuries or chest injuries on which REBOA
has no benefit and sometimes can be harmful. Moreover,
the evidence was limited to observational studies. In all
studies, the clinical indication to REBOA was haemor-
rhage from a pelvic fracture or abdominal injury, condi-
tions that recognize optimal clinical results with
standard damage control approaches, such as abdominal
or extraperitoneal packing [38]. Both manoeuvres im-
prove haemodynamics and survival and are easily per-
formed by surgical personnel with specific experience.
REBOA stops flow totally or partially below the occlu-
sion level (zone I or III), inflation limits the bleeding but
also does produce ischemia both regionally and system-
ically. Given the tendency towards reperfusion injury,
REBOA has a limited time window of application before
the complications overcome the benefit of intervention
[39, 40]. REBOA is likely not clinically better than the
standard and more consolidated damage control inter-
ventions for bleeding control in non-compressible torso
haemorrhagic shock, but can be implemented as a life-
saving haemostatic bridge, if damage control surgery is
not immediately available after prompt evaluation and
indications based on clinical characteristics of patients.
Furthermore, many variables can affect survival in this
category of patients: pre-hospital time, prompt recogni-
tion of bleeding site(s), availability of expert surgeon,
time to operating room, appropriate transfusion proto-
col, physiology of the patient. Time to operating room
and physiologic state of patients may predict outcome as
importantly as does whether a REBOA is used [41]. Due
to these considerations, further investigations with an
adequate volume of cases considering all possible con-
founders can help to understand the efficacy of REBOA
in torso haemorrhages.
Limitations
Our review is the most comprehensive effort in the
management of haemorrhage in major trauma patients;
however, several limitations must be addressed. Al-
though our quantitative synthesis shows that REBOA is
associated with lower mortality when compared to RT,
these results could be flawed by the presence of patient
selection for indication bias and survival bias within the
individual observational studies [42]. Indication bias
arises when patients are classified on the basis of the
Fig. 3 Adjusted odds ratios for mortality at 24 h (REBOA vs control — subgroups: vs RT; vs RT with REBOA; vs no-REBOA)
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non-randomized intervention they received during the
natural course of their medical treatment. Survival bias
appears when comparing groups in which patients may
die before treatment is initiated [43]. Clinical conditions
(e.g. cardiac arrest) strongly influenced the treatment in-
dication and so the assignment of patients in the RT or
no-REBOA group. In the emergency department, RT is
performed in patients who are experiencing post-
traumatic cardiac arrest, while REBOA is indicated for
trauma patients who are in an uncontrolled haemor-
rhagic shock for a pelvic fracture or abdominal fluid de-
tected on an initial ultrasonography scan in the trauma
bay [27]. For these reasons, some studies may have an
inadequate control group (i.e. patients who did not
undergo REBOA placement and/or RT). We have
overcome this limitation by subgrouping the patients,
who underwent thoracotomy in the ED, patients who
underwent REBOA and those who did not undergo
REBOA. Unfortunately, we did not find RCTs, the most
reliable evidence on the effectiveness of interventions
[44] which minimize the risk of bias and confounding
factors influencing the results [45]. Even if performing
RCTs can be unethical in life-threatening situations,
challenging to design and deliver it is not impossible: a
recent mapping review has highlighted that evidence
from trials in prehospital trauma is sparse and can
be prioritized [46]. We call for the need for further
randomized trials of REBOA vs RT and REBOA vs
no-REBOA in order to assure well-matched
patients.
Table 3 Volume of blood components
Autore Outcome Units REBOA Controla p value
Cryoprecipitate
Dubose 2016 [24] Cryoprecipitate 24 h Median (IQR) 1 (11) 0 (1) 0.14
Garcia 2020 [25] Cryoprecipitate 6 h Median (IQR) 6.5 (0–10) 0 (0–0) 0.21
Crystalloids
Garcia 2020 [25] Crystalloids 24 h millilitres Median (IQR) 4649 (3290–6329) 4420 (2705–6350) 0.13
Dubose 2016 [24] Crystalloids 24 h litres Median (IQR) 4 (5) 3 (5) 0.12
Plasma
Joseph 2019 [27] Plasma 24 h Median (IQR) 9 (6–20) 10 (7–20) 0.17
Brenner 2018 [23] Plasma 24 h Median (IQR) 9 (16) 4 (9) 0.11
DuBose 2016 [24] Plasma 24 h Median (IQR) 14.5 (18) 6 (18) < 0.001
Joseph 2019 [27] Plasma 4 h Median (IQR) 3 (2–5) 3 (2–6) 0.001
Garcia 2020 [25] Plasma 6 h Median (IQR) 4 (2.5–6) 0 (0–4) < 0.001
Platelets
Joseph 2019 [27] Platelets 24 h Median (IQR) 7 (3–13) 8 (3–12) < 0.001
DuBose 2016 [24] Platelets 24 h Median (IQR) 5.5 (12) 1.5 (11) 0.5
Joseph 2019 [27] Platelets 4 h Median (IQR) 4 (3–9) 4 (3–8) 0.05
Garcia 2020 [25] Platelets 6 h Median (IQR) 0.5 (0–6) 0 (0–0) 0.05
PRBCs
Joseph 2019 [27] PRBCs 24 h Median (IQR) 9 (5–20) 10 (4–21) 0.3988
Brenner 2018 [23] PRBCs 24 h Median (IQR) 10 (21) 7.8 (10) 0.654
DuBose 2016 [24] PRBCs 24 h Median (IQR) 20.5 (18) 13.5 (18) 0.343
Joseph 2019 [27] PRBCs 4 h Median (IQR) 6 (3–8) 7 (3–9) 0.872
Garcia 2020 [25] PRBCs 6 h Median (IQR) 5 (3–9) 2 (0–4) 0.149
Total amount of transfusion
Aso 2016 [22] Total amount of transfusion within
1 d after admission: average (SD), mL
media (sd) 2.396 (1.872) 2.820 (2.782) 0.697
Transfusion in number of patients
Abe 2016 [21] Transfusion in number of patients n (%) 542 (85%) 197 (74%) 0.001
Yamamoto 2019 [30] Transfusion in number of patients n (%) 111 (95%) 113 (97%) < 0.001
aRT (Abe 2016, Aso 2016, DuBose 2016, Brenner 2018), RT + REBOA (Matsumara 2017), non-REBOA (Yamamoto 2019, Joseph 2019, Garcia 2020)
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The use of REBOA should take into account skills,
high expertise on their applicability [47, 48], acceptabil-
ity of clinicians and cost [49, 50]. For optimal success,
REBOA requires careful system-wide multidisciplinary
implementation [51]. Institutions are responsible for
analysing qualifications for providers to perform REBOA
[42] as well as evaluating system capabilities [52]. A very
small number of trauma centres have an extensive
experience with REBOA; thus, these results may not be
generalizable to all trauma centres [42]. Finally, we in-
cluded studies with a heterogeneous use of REBOA
which should be taken into account (catheter size, occlu-
sion zone, protocols, physiologic indications for REBOA
insertion).
Conclusion
Among non-compressible torso injuries, we found a
positive effect on overall mortality of REBOA when
compared to RT but no valid conclusions can be made
due to selection bias, while not statistically significant
the comparison of REBOA versus no-REBOA from
which the most valuable contribution for clinical prac-
tice is drawn. REBOA should be promoted in specific
training programs in an experimental setting in order to
test its effectiveness as temporary management to haem-
orrhage control and resuscitation. Prospectively assessed
data, with specific inclusion and exclusion criteria,
ideally in a randomized controlled trial, should be
planned in order to limit the bias coming from observa-
tional studies. Future studies must address specific indi-
cations for REBOA to know which population could
benefit the most from its use.
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